Lyons et al. used the mitogen-activated protein kinase 1 (MEK)-inhibitor trametinib in a woman with recurrent small cell NECC and a Kirsten rat sarcoma gene (KRAS)-mutated tumor [144]. Here, MAP2K7 is linked to neoplasm.